Gamida Cell to Present at the BTIG Virtual Biotechnology Conference
August 03 2021 - 8:00AM
Business Wire
Gamida Cell Ltd. (Nasdaq: GMDA), an advanced cell therapy
company committed to cures for blood cancers and serious blood
diseases, today announced that the company will participate in a
fireside chat at the BTIG Virtual Biotechnology Conference on
Tuesday, August 10, 2021 at 3:00 p.m. ET.
The live webcast will be available on BTIG’s conference website
at the time of the event, after which it will be available through
BTIG’s research access.
In the fourth quarter of 2021, Gamida Cell is targeting a BLA
submission for omidubicel, the first potential approval of a cell
therapy for blood cancer patients in need of an allogeneic bone
marrow transplant. In the second half of 2021, the Company is
planning an IND submission to support the initiation of a Phase 1/2
clinical study of cryopreserved, off-the-shelf GDA-201 in patients
with follicular and diffuse large b-cell lymphomas.
About Gamida Cell
Gamida Cell is an advanced cell therapy company committed to
cures for patients with blood cancers and serious blood diseases.
We harness our cell expansion platform to create therapies with the
potential to redefine standards of care in areas of serious medical
need. For additional information, please visit www.gamida-cell.com
or follow Gamida Cell on LinkedIn or Twitter at @GamidaCellTx.
Cautionary Note Regarding Forward Looking Statements
This press release contains forward-looking statements as that
term is defined in the Private Securities Litigation Reform Act of
1995, including with respect to anticipated regulatory submissions,
which statements are subject to a number of risks, uncertainties
and assumptions, including, but not limited to the scope, progress
and expansion of Gamida Cell’s clinical trials and ramifications
for the cost thereof; and clinical, scientific, regulatory and
technical developments. In light of these risks and uncertainties,
and other risks and uncertainties that are described in the Risk
Factors section and other sections of Gamida Cell’s Annual Report
on Form 20-F, filed with the Securities and Exchange Commission
(SEC) on March 9, 2021, as amended, and other filings that Gamida
Cell makes with the SEC from time to time (which are available at
http://www.sec.gov), the events and circumstances discussed in such
forward-looking statements may not occur, and Gamida Cell’s actual
results could differ materially and adversely from those
anticipated or implied thereby. Any forward-looking statements
speak only as of the date of this press release and are based on
information available to Gamida Cell as of the date of this
release.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210803005052/en/
For investors: Stephanie Ascher Stern Investor Relations, Inc.
stephanie.ascher@sternir.com 1-212-362-1200
For media: Rhiannon Jeselonis Ten Bridge Communications
rhiannon@tenbridgecommunications.com 1-978-417-1946
Gamida Cell (NASDAQ:GMDA)
Historical Stock Chart
From Sep 2024 to Oct 2024
Gamida Cell (NASDAQ:GMDA)
Historical Stock Chart
From Oct 2023 to Oct 2024